Editorial
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jun 15, 2025; 17(6): 105062
Published online Jun 15, 2025. doi: 10.4251/wjgo.v17.i6.105062
Kinesin family member 14 in digestive tract malignancies: Oncogenic mechanisms, clinical implications, and therapeutic prospects
De-Hui Li, Chang Qiao, Yu-Tong Han, Jian-Li Ge
De-Hui Li, Oncology Department II, The First Affiliated Hospital of Hebei University of Chinese Medicine (Hebei Province Hospital of Chinese Medicine), Key Laboratory of Integrated Chinese and Western Medicine for Gastroenterology Research, Hebei Industrial Technology Institute for Traditional Chinese Medicine Preparation, Shijiazhuang 050000, Hebei Province, China
Chang Qiao, Graduate School, Hebei University of Chinese Medicine, Shijiazhuang 050000, Hebei Province, China
Yu-Tong Han, Class 9, Department of Neurology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China
Jian-Li Ge, Department of Peripheral Vascular, The First Affiliated Hospital of Hebei University of Chinese Medicine (Hebei Province Hospital of Chinese Medicine), Shijiazhuang 050000, Hebei Province, China
Co-corresponding authors: De-Hui Li and Jian-Li Ge.
Author contributions: Li DH designed the overall concept and outline of the manuscript; Ge JL and Han YT contributed to the writing and editing of the manuscript and a review of the literature; Qiao C drew the figure for the manuscript. All authors have read and approved the final manuscript.
Supported by the 2023 Government-funded Project of the Outstanding Talents Training Program in Clinical Medicine, No. ZF2023165; Key Research and Development Projects of Hebei Province, No. 18277731D; Natural Science Foundation of Hebei Province, No. H202423105; and Hebei Provincial Administration of Traditional Chinese Medicine, Scientific Research Project, No. 2020014.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: De-Hui Li, MD, Oncology Department II, The First Affiliated Hospital of Hebei University of Chinese Medicine (Hebei Province Hospital of Chinese Medicine), Key Laboratory of Integrated Chinese and Western Medicine for Gastroenterology Research, Hebei Industrial Technology Institute for Traditional Chinese Medicine Preparation, No. 389 Zhongshan East Road, Chang’an District, Shijiazhuang 050000, Hebei Province, China. 258289951@qq.com
Received: January 11, 2025
Revised: March 20, 2025
Accepted: April 8, 2025
Published online: June 15, 2025
Processing time: 154 Days and 3 Hours
Core Tip

Core Tip: Kinesin family member 14 (KIF14) is pivotal in malignant tumors of the digestive tract. As a crucial driver protein, its elevated expression is intricately linked with tumor biology, drug resistance, progression-free survival, and overall survival, highlighting its potential as a biomarker for early diagnosis, disease monitoring, and prognosis evaluation. Furthermore, recent advancements in targeting KIF14 as a therapeutic target and the regulatory effects of traditional Chinese medicine provide promising new pathways for improving treatment outcomes and enhancing patient prognosis in digestive tract malignancies.